MX2022014454A - Variantes de la region fc de inmunoglobulina que comprenden mutaciones que mejoran la estabilidad. - Google Patents

Variantes de la region fc de inmunoglobulina que comprenden mutaciones que mejoran la estabilidad.

Info

Publication number
MX2022014454A
MX2022014454A MX2022014454A MX2022014454A MX2022014454A MX 2022014454 A MX2022014454 A MX 2022014454A MX 2022014454 A MX2022014454 A MX 2022014454A MX 2022014454 A MX2022014454 A MX 2022014454A MX 2022014454 A MX2022014454 A MX 2022014454A
Authority
MX
Mexico
Prior art keywords
stability
immunoglobulin
region variants
enhancing mutations
variant
Prior art date
Application number
MX2022014454A
Other languages
English (en)
Inventor
Eric Escobar-Cabrera
Geneviève Desjardins
Antonios Samiotakis
Gavin Carl Jones
Original Assignee
Zymeworks Bc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Bc Inc filed Critical Zymeworks Bc Inc
Publication of MX2022014454A publication Critical patent/MX2022014454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen variantes de Fc que comprenden una o más mutaciones de aminoácidos que mejoran la estabilidad de la variante de Fc en comparación con un Fc original que no incluye la una o más mutaciones de aminoácidos, así como polipéptidos que comprenden una variante de Fc y polinucleótidos que codifican una variante de Fc.
MX2022014454A 2020-05-20 2021-05-20 Variantes de la region fc de inmunoglobulina que comprenden mutaciones que mejoran la estabilidad. MX2022014454A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027569P 2020-05-20 2020-05-20
US202163163686P 2021-03-19 2021-03-19
PCT/CA2021/050691 WO2021232163A1 (en) 2020-05-20 2021-05-20 Immunoglobulin fc region variants comprising stability-enhancing mutations

Publications (1)

Publication Number Publication Date
MX2022014454A true MX2022014454A (es) 2023-02-27

Family

ID=78708881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014454A MX2022014454A (es) 2020-05-20 2021-05-20 Variantes de la region fc de inmunoglobulina que comprenden mutaciones que mejoran la estabilidad.

Country Status (10)

Country Link
US (1) US20230303715A1 (es)
EP (1) EP4153620A1 (es)
JP (1) JP2023526114A (es)
KR (1) KR20230043790A (es)
CN (1) CN116133685A (es)
AU (1) AU2021274316A1 (es)
BR (1) BR112022023570A2 (es)
CA (1) CA3144731A1 (es)
MX (1) MX2022014454A (es)
WO (1) WO2021232163A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240166750A1 (en) * 2022-10-25 2024-05-23 Ablynx N.V. GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
WO2006031370A2 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
MX2011007833A (es) * 2009-01-23 2011-10-06 Biogen Idec Inc Polipeptidos fc estabilizados con funcion efectora reducida y metodos de uso.
WO2012032080A1 (en) * 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
CA2830254C (en) * 2011-03-16 2019-09-10 Amgen Inc. Fc variants

Also Published As

Publication number Publication date
KR20230043790A (ko) 2023-03-31
US20230303715A1 (en) 2023-09-28
CA3144731A1 (en) 2021-11-25
CN116133685A (zh) 2023-05-16
AU2021274316A1 (en) 2023-02-02
BR112022023570A2 (pt) 2023-01-24
JP2023526114A (ja) 2023-06-20
WO2021232163A1 (en) 2021-11-25
EP4153620A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
PH12019500280A1 (en) Trimer stabilizing hiv envelope protein mutations
MX2020010075A (es) Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
EA202190827A1 (ru) Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
MX2017005150A (es) Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
EA201691576A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
MX2022014454A (es) Variantes de la region fc de inmunoglobulina que comprenden mutaciones que mejoran la estabilidad.
MX2020004206A (es) Variantes il-2 modificadas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunitarias.
AU2017261249A1 (en) Adeno-associated virus polynucleotides, polypeptides and virions
EA201891573A1 (ru) Конъюгат терапевтических ферментов
MX2018011542A (es) Moleculas biespecificas de celulas t activadas por proteasas.
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
EA202090540A1 (ru) Ген, придающий устойчивость к патогенному грибу
MX2019010155A (es) Arnm de cftr optimizado por codón novedoso.
MX2020007628A (es) Composiciones y metodos de uso.
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
MX2021000322A (es) Enzimas de variante fosfopentomutasa modificada geneticamente.
UY36565A (es) Variantes de polipéptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, asi como procedimientos para la division de toxinas de fusarium
MX2019009860A (es) Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea.
EA202192637A1 (ru) Полинуклеотиды, композиции и способы для экспрессии полипептида
MX2021000323A (es) Enzimas de variante de pantotenato quinasa modificadas geneticamente.
EA202191123A1 (ru) Миниатюризированные дистрофины и их применения
FR3058159B1 (fr) Variants de polypeptide fc presentant une demi-vie augmentee
AU2019350356A8 (en) Arginase1 polypeptides
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.